Table 4.

Self-reported History of Multivitamin Use and Prostate Cancer Risk

	Recency of Multivitamin Use at Baseline			Cumulative Years of Multivitamin Use at Baseline
	Never n=17,719	Former n=2,821	Current n=14,347	None n=17,719	<5 years n=5,502	≥5 years n=11,666
Total PCa
HR (95% CI)1	Ref	0.98 (0.91–1.06)	1.01 (0.97–1.06)	Ref	0.97 (0.92–1.03)	1.02 (0.98–1.07)
IDR (95% CI)2	Ref	0.97 (0.85, 1.12)	1.01 (0.93, 1.09)	Ref	0.96 (0.86–1.07)	1.03 (0.95–1.11)
High-Grade PCa (Gleason 7–10) 3
HR (95% CI)1	Ref	1.13 (0.99–1.30)	1.19 (1.10–1.28)	Ref	1.10 (1.00–1.22)	1.21 (1.12–1.31)
IDR (95% CI)2	Ref	0.93 (0.72, 1.21)	1.10 (0.96, 1.26)	Ref	0.97 (0.77–1.24)	1.20 (1.01–1.44)
	Excluding Men who had a biopsy prior to SELECT Trial entry
	N=16,156	N=2,585	N=12,739	N=16,156	N=5,020	N=10,304
Total PCa
HR (95% CI)1	Ref	0.88 (0.81–0.96)	1.02 (0.97–1.06)	Ref	0.92 (0.87–0.98)	1.03 (0.98–1.08)
IDR (95% CI)2	Ref	0.95 (0.82, 1.10)	1.01 (0.93, 1.09)	Ref	0.94 (0.84–1.05)	1.03 (0.95–1.12)
High-Grade PCa (Gleason 7–10) 3
HR (95% CI)1	Ref	0.93 (0.80–1.07)	1.15 (1.06–1.24)	Ref	0.99 (0.88–1.10)	1.17 (1.08–1.27)
IDR (95% CI)2	Ref	0.86 (0.65, 1.15)	1.07 (0.93, 1.24)	Ref	0.94 (0.77–1.16)	1.09 (0.94–1.27)

¹Model 1: Hazard ratios are adjusted for age (linear), race (white, black, other), family history of prostate cancer, longitudinal PSA (linear; time-dependent); longitudinal DRE (normal vs abnormal; time-dependent), negative biopsy at baseline or on study (yes vs no; time-dependent).

²Incidence Density Hazard ratios are adjusted for age, PSA, DRE status within the prior year, family history of prostate cancer, prior negative biopsy and race; Imputation was performed separately for any and high-grade PCa.

³For the -specific models, participants with a different grade of cancer are censored at diagnosis date, and cases with no known Gleason score (N=203) are removed from the analysis.